Recent Updates
Recently added Catalysts

Chronic Idiopathic Constipation: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$924Muniverse median $1.20B
Allocated capital$462M$924M competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank210/299crowding rank 215

Chronic Idiopathic Constipation is uncontested. Ardelyx (ARDX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Tenapanor in phase 3.

There is no public comparable to price it against. ARDX spreads its $924M market cap across 2 indications, so $462M of it is allocated here.

The one programme here is in late-stage development, but it carries no dated catalyst in the next 12 months.

$462M of allocated capital sits in Chronic Idiopathic Constipation, ranking it 210th of 299 indications by the money committed to it.

Companies developing drugs for Chronic Idiopathic Constipation 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ARDXArdelyxTenapanorPhase 31$924MNo2 31 Dec 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Chronic Idiopathic Constipation counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Chronic Idiopathic Constipation has one competitor and a median of $924M.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Long Chain Fatty Acid Oxidation Disorders1 company · $488M · median $1.5BUncontestedGestational Diabetes1 company · $424M · median $1.3BUncontestedChronic Kidney Disease Stage 3 and 41 company · $601M · median $1.2BUncontestedGout1 company · $211M · median $211MUncontestedArrhythmogenic Right Ventricular Cardiomyopathy2 companies · $210M · median $277MOrphan cornerProteinuric Kidney Disease1 company · $719M · median $1.4BUncontestedAnemia Associated With Chronic Kidney Disease1 company · $180M · median $1.6BUncontestedVenous Leg Ulcers1 company · $170M · median $170MUncontested

Chronic Idiopathic Constipation pipeline questions

Which biotech companies are developing drugs for Chronic Idiopathic Constipation?

Ardelyx (ARDX, Tenapanor, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Chronic Idiopathic Constipation.

How advanced is the Chronic Idiopathic Constipation pipeline?

Of the 1 clinical-stage programme in Chronic Idiopathic Constipation, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Chronic Idiopathic Constipation?

No. ARDX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Chronic Idiopathic Constipation, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map